Patient characteristics at screening (intention-to-treat population)
| FF/UMEC/VI | Non-ELLIPTA MITT | Total | |
| Patients | 1545 | 1547 | 3092 |
| Age years | 67.8±8.78 | 67.8±8.59 | 67.8±8.68 |
| Male | 837 (54) | 818 (53) | 1655 (54) |
| BMI kg·m−2 | 27.84±5.93 n=1536 | 28.05±6.05 n=1538 | 27.95±5.99 n=3074 |
| COPD exacerbation history in the prior 12 months | |||
| Moderate | |||
| 0 | 409 (26) | 405 (26) | 814 (26) |
| 1 | 639 (41) | 645 (42) | 1284 (42) |
| ≥2 | 497 (32) | 497 (32) | 994 (32) |
| Severe | |||
| 0 | 1349 (87) | 1361 (88) | 2710 (88) |
| 1 | 155 (10) | 139 (9) | 294 (10) |
| ≥2 | 41 (3) | 47 (3) | 88 (3) |
| Moderate/severe | |||
| 0 | 363 (23) | 361 (23) | 724 (23) |
| 1 | 615 (40) | 610 (39) | 1225 (40) |
| ≥2 | 567 (37) | 576 (37) | 1143 (37) |
| CAT score | 20.8±6.76 n=1543 | 20.5±6.62 n=1547 | 20.7±6.69 n=3090 |
| Peripheral blood eosinophil count# | n=605 | n=572 | n=1177 |
| <150 cells·µL−1 | 208 (34) | 223 (39) | 431 (37) |
| ≥150 cells·µL−1 | 397 (66) | 349 (61) | 746 (63) |
| Actual prior medication use strata | |||
| ICS+LAMA+LABA | 1226 (79) | 1235 (80) | 2461 (80) |
| ICS+LABA | 126 (8) | 126 (8) | 252 (8) |
| LABA+LAMA | 192 (12) | 183 (12) | 375 (12) |
| Missing¶ | 1 (<1) | 3 (<1) | 4 (<1) |
Data are presented as n, mean±sd or n (%). FF: fluticasone furoate; UMEC: umeclidinium; VI: vilanterol; MITT: multiple-inhaler triple therapy; BMI: body mass index; CAT: COPD Assessment Test; ICS: inhaled corticosteroid; LAMA: long-acting muscarinic receptor antagonist; LABA: long-acting β2-agonist. #: historical eosinophils were recorded as the most recent measure taken within the previous 36 months; ¶: stratum is considered missing if the combination of maintenance treatments taken in the 14 days prior to randomisation do not meet any of the three defined strata groups.